Argenx
ARGX
#470
Rank
A$73.74 B
Marketcap
A$1,192
Share price
-0.34%
Change (1 day)
17.79%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2025 (TTM): A$13.55

According to Argenx 's latest financial reports the company's current EPS (TTM) is A$12.52. In 2024 the company made an earnings per share (EPS) of A$19.64 an increase over its 2023 EPS that were of A-$7.28.

EPS history for Argenx from 2011 to 2025

Annual EPS

Year EPS Change
2025 (TTM)A$13.55-31.04%
2024A$19.64-369.77%
2023A-$7.28-60.46%
2022A-$18.4263.33%
2021A-$11.28-40.37%
2020A-$18.91183.47%
2019A-$6.67123.09%
2018A-$2.9954.93%
2017A-$1.9314.07%
2016A-$1.6913.05%
2015A-$1.50-36.34%
2014A-$2.35209.04%
2013A-$0.76-33.99%
2012A-$1.15185.59%
2011A-$0.40